Menta Capital LLC raised its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 20.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 7,163 shares of the medical research company’s stock after purchasing an additional 1,196 shares during the period. Menta Capital LLC’s holdings in Bio-Rad Laboratories were worth $1,621,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Northwestern Mutual Investment Management Company LLC grew its holdings in Bio-Rad Laboratories by 0.4% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 3,596 shares of the medical research company’s stock valued at $514,000 after purchasing an additional 13 shares during the last quarter. World Asset Management Inc grew its holdings in Bio-Rad Laboratories by 1.4% in the second quarter. World Asset Management Inc now owns 1,025 shares of the medical research company’s stock valued at $232,000 after purchasing an additional 14 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in Bio-Rad Laboratories by 1.8% in the second quarter. Teacher Retirement System of Texas now owns 1,666 shares of the medical research company’s stock valued at $377,000 after purchasing an additional 29 shares during the last quarter. US Bancorp DE grew its holdings in Bio-Rad Laboratories by 0.8% in the second quarter. US Bancorp DE now owns 4,224 shares of the medical research company’s stock valued at $956,000 after purchasing an additional 34 shares during the last quarter. Finally, State of Wisconsin Investment Board grew its holdings in Bio-Rad Laboratories by 1.0% in the second quarter. State of Wisconsin Investment Board now owns 4,187 shares of the medical research company’s stock valued at $948,000 after purchasing an additional 40 shares during the last quarter. 62.84% of the stock is currently owned by institutional investors.

In related news, EVP Michael Crowley sold 700 shares of Bio-Rad Laboratories stock in a transaction on Friday, August 11th. The stock was sold at an average price of $215.91, for a total value of $151,137.00. Following the transaction, the executive vice president now directly owns 2,060 shares in the company, valued at approximately $444,774.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 28.29% of the company’s stock.

WARNING: This piece was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/23/menta-capital-llc-boosts-holdings-in-bio-rad-laboratories-inc-bio.html.

Shares of Bio-Rad Laboratories, Inc. (BIO) opened at 228.68 on Friday. The stock has a 50 day moving average price of $220.74 and a 200 day moving average price of $217.89. Bio-Rad Laboratories, Inc. has a 12 month low of $154.89 and a 12 month high of $242.79. The stock has a market capitalization of $6.78 billion, a P/E ratio of 451.94 and a beta of 0.93.

Several analysts have weighed in on BIO shares. Deutsche Bank AG raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and lowered their target price for the company from $220.00 to $195.00 in a report on Wednesday, June 28th. Zacks Investment Research downgraded Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. BidaskClub upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price objective on the stock. Finally, TheStreet downgraded Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Bio-Rad Laboratories presently has an average rating of “Buy” and a consensus target price of $240.80.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.